Archives
-
Standardized Whole-Blood Stimulation in Immunometabolism
2026-09-17
Zhao and colleagues present a standardized fresh whole-blood platform for testing how metabolic interventions reshape stimulus-specific immune responses. The protocol links controlled pattern-recognition or microbial stimulation with pathway-directed inhibition and cytokine quantification, supporting more reproducible immunometabolism and cohort studies.
-
TCAIM Regulation of OGDH in Mitochondrial Metabolism
2026-09-17
The 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and lowers its protein abundance through HSPA9 and LONP1. By connecting mitochondrial proteostasis with control of a rate-limiting TCA-cycle enzyme, the work reveals a post-translational mechanism that suppresses OGDH complex activity and reshapes carbohydrate metabolism.
-
FCCP: From Bioenergetic Stress to Translational Insight
2026-09-16
FCCP is more than an oxidative phosphorylation uncoupler. By linking mitochondrial proton-gradient dissipation with HIF signaling, cancer metabolism, and the newly described CO2-dependent communication between axons and Schwann cells, this article outlines how translational researchers can use FCCP to build more informative mechanistic experiments.
-
TCAIM, OGDH Proteolysis, and Mitochondrial Metabolism
2026-09-16
The reference study identifies TCAIM as a DNAJC co-chaperone that selectively binds the OGDH subunit of the α-ketoglutarate dehydrogenase complex and promotes its mtHSP70- and LONP1-dependent degradation. Its structural, cellular, and mouse data support a model in which mitochondrial proteostasis directly adjusts metabolic enzyme abundance, activity, and bioenergetic state.
-
Ranolazine: Mechanism and Research Workflow
2026-09-15
Ranolazine is an anti-ischemic agent that primarily inhibits the cardiac late sodium current and limits sodium-dependent calcium overload. Its metabolic profile also supports glucose oxidation enhancement and experimental studies of fatty acid oxidation, myocardial relaxation, and cardiac ischemia.
-
Ibrexafungerp Against Fluconazole-Resistant C. auris
2026-09-15
Wiederhold and colleagues evaluated ibrexafungerp against fluconazole-resistant Candida auris using susceptibility testing and a delayed-treatment neutropenic mouse model. The study found reproducible in vitro activity and improved survival and renal fungal burden outcomes with higher-dose ibrexafungerp, supporting further investigation of orally administered glucan-synthesis inhibitors.
-
Oligo-dT Membrane Design for mRNA Capture
2026-09-14
The reference study establishes design rules for improving oligo-dT affinity membranes by linking ligand density, nanoscale clustering, pore size, and mRNA dimensions. Its local-density model and super-resolution measurements show why excess ligand does not necessarily improve capture and provide practical guidance for purifying long polyadenylated transcripts.
-
Ouabain at the Vascular Translation Frontier
2026-09-14
Ouabain is more than a classical sodium-potassium pump blocker: it is a mechanistic probe for testing how ion gradients, calcium handling, and vascular reserve interact across translational models. This article connects Ouabain-based perturbation strategies with recent findings on metformin-driven endothelium-dependent hyperpolarization, while providing practical guidance for cardiovascular research, assay design, and heart failure model interpretation.
-
LY364947 for TGF-β Signaling and EMT
2026-09-13
LY364947 is a selective TGF-β type I receptor kinase inhibitor for connecting proximal Smad2 signaling to EMT, fibrosis, cancer, and retinal injury phenotypes. This workflow shows how to manage DMSO stocks, pair rapid phospho-readouts with longer EMT endpoints, and interpret pathway effects alongside the latest pancreatic cancer findings.
-
HyperScribe™ Poly (A) Tailing Kit Workflow
2026-09-12
Build more consistent RNA workflows by adding a defined poly(A) tail to HyperScribe T7 transcripts before translation, transfection, or micro-injection. This practical guide connects tailing control with the chemically modified mRNA strategy used in a thrombopoietin mouse study while separating established evidence from conditions that require laboratory optimization.
-
Thiazovivin (A5506): Practical ROCK Inhibitor Guide
2026-09-11
Thiazovivin is a ROCK inhibitor for workflows in which dissociation-related cell loss or inefficient fibroblast reprogramming limits results. This guide covers stock handling, control design, and QC for induced pluripotent stem cell generation and human embryonic stem cell survival, while defining why the compound should remain within validated research workflows and not be used for diagnostic or clinical purposes.
-
Protecting CerS6 Biology During Protein Extraction
2026-09-11
CerS6 activity depends on more than protein abundance: the reference study links basal Asn18 glycosylation to catalytic function and downstream signaling. This article translates that insight into a practical extraction strategy using an EDTA-free protease inhibitor cocktail while defining what such protection can—and cannot—prove.
-
Multiplex PBMC Assay for Immunomodulator Screening
2026-09-10
Brox and Hackstein developed a human PBMC-based multiplex flow cytometry assay that measures T-cell proliferation and activation alongside B-cell costimulatory responses. Its use of defined stimulation conditions, multiparametric readouts, and Z-factor validation offers a practical framework for higher-resolution immunomodulator screening and immune pathway profiling.
-
O-propargyl-puromycin (OPP) for Translation Flux
2026-09-10
O-propargyl-puromycin (OPP) converts nascent protein synthesis into a measurable click-chemistry signal. This article explains how to use OPP to interrogate the Pcbp1–Fdxr–mitochondrial axis in B cells while distinguishing translation flux from mitochondrial function and cell viability.
-
Vernakalant Hydrochloride: Atrial Selectivity in Practice
2026-09-09
Vernakalant Hydrochloride, also known as RSD1235, offers a useful model for studying atrial-selective multichannel pharmacology. This article explains how ion-channel selectivity, exposure matching, and KCa2 assay controls improve atrial fibrillation research decisions.